Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

Oncology & Cancer

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to a study scheduled to ...

Health

Clinical guidelines from specialty societies often biased

Clinical practice guidelines issued by specialty societies in North America often recommend health care services linked to their specialties, in contrast with European guidelines and those from independent organizations, ...

Oncology & Cancer

Poll: Patients, caregivers worry about cost of cancer care

(HealthDay)—In addition to fear of pain and suffering, Americans worry about cancer-related expenses, according to the results of the American Society of Clinical Oncology (ASCO) 2018 National Cancer Opinion Survey.

page 11 from 39